• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

验证 UKPDS 风险引擎在 2 型糖尿病患者中的外部有效性。

External validation of the UK Prospective Diabetes Study (UKPDS) risk engine in patients with type 2 diabetes.

机构信息

Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Str 6.131, PO Box 85500, 3508 GA Utrecht, The Netherlands.

出版信息

Diabetologia. 2011 Feb;54(2):264-70. doi: 10.1007/s00125-010-1960-0. Epub 2010 Nov 14.

DOI:10.1007/s00125-010-1960-0
PMID:21076956
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3017299/
Abstract

AIMS/HYPOTHESIS: Treatment guidelines recommend the UK Prospective Diabetes Study (UKPDS) risk engine for predicting cardiovascular risk in patients with type 2 diabetes, although validation studies showed moderate performance. The methods used in these validation studies were diverse, however, and sometimes insufficient. Hence, we assessed the discrimination and calibration of the UKPDS risk engine to predict 4, 5, 6 and 8 year cardiovascular risk in patients with type 2 diabetes.

METHODS

The cohort included 1,622 patients with type 2 diabetes. During a mean follow-up of 8 years, patients were followed for incidence of CHD and cardiovascular disease (CVD). Discrimination and calibration were assessed for 4, 5, 6 and 8 year risk. Discrimination was examined using the c-statistic and calibration by visually inspecting calibration plots and calculating the Hosmer-Lemeshow χ(2) statistic.

RESULTS

The UKPDS risk engine showed moderate to poor discrimination for both CHD and CVD (c-statistic of 0.66 for both 5 year CHD and CVD risks), and an overestimation of the risk (224% and 112%). The calibration of the UKPDS risk engine was slightly better for patients with type 2 diabetes who had been diagnosed with diabetes more than 10 years ago compared with patients diagnosed more recently, particularly for 4 and 5 year predicted CVD and CHD risks. Discrimination for these periods was still moderate to poor.

CONCLUSIONS/INTERPRETATION: We observed that the UKPDS risk engine overestimates CHD and CVD risk. The discriminative ability of this model is moderate, irrespective of various subgroup analyses. To enhance the prediction of CVD in patients with type 2 diabetes, this model should be updated.

摘要

目的/假设:治疗指南推荐 UKPDS 风险引擎来预测 2 型糖尿病患者的心血管风险,尽管验证研究表明其性能中等。然而,这些验证研究使用的方法多种多样,有时还不够充分。因此,我们评估了 UKPDS 风险引擎预测 2 型糖尿病患者 4、5、6 和 8 年心血管风险的区分度和校准度。

方法

该队列包括 1622 名 2 型糖尿病患者。在平均 8 年的随访期间,患者因冠心病和心血管疾病(CVD)的发生而被随访。使用 c 统计量评估 4、5、6 和 8 年风险的区分度,通过视觉检查校准图和计算 Hosmer-Lemeshow χ(2)统计量评估校准度。

结果

UKPDS 风险引擎对冠心病和心血管疾病的区分度均为中等至较差(5 年冠心病和心血管疾病风险的 c 统计量分别为 0.66),并且风险高估(224%和 112%)。对于诊断时间超过 10 年的 2 型糖尿病患者,UKPDS 风险引擎的校准情况略好于最近诊断的患者,尤其是对于 4 年和 5 年预测的心血管疾病和冠心病风险。这些时期的区分度仍然是中等至较差。

结论/解释:我们观察到 UKPDS 风险引擎高估了冠心病和心血管疾病的风险。该模型的判别能力中等,无论进行何种亚组分析都是如此。为了提高 2 型糖尿病患者心血管疾病的预测能力,应更新该模型。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e994/3017299/31b07f566d86/125_2010_1960_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e994/3017299/31b07f566d86/125_2010_1960_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e994/3017299/31b07f566d86/125_2010_1960_Fig1_HTML.jpg

相似文献

1
External validation of the UK Prospective Diabetes Study (UKPDS) risk engine in patients with type 2 diabetes.验证 UKPDS 风险引擎在 2 型糖尿病患者中的外部有效性。
Diabetologia. 2011 Feb;54(2):264-70. doi: 10.1007/s00125-010-1960-0. Epub 2010 Nov 14.
2
External validation of the UK prospective diabetes study (UKPDS) risk engine in patients with type 2 diabetes identified in the national diabetes program in Iran.在伊朗国家糖尿病项目中识别出的2型糖尿病患者中对英国前瞻性糖尿病研究(UKPDS)风险评估模型进行外部验证。
J Diabetes Metab Disord. 2023 May 25;22(2):1145-1150. doi: 10.1007/s40200-023-01224-2. eCollection 2023 Dec.
3
Prognostic value of the Framingham cardiovascular risk equation and the UKPDS risk engine for coronary heart disease in newly diagnosed Type 2 diabetes: results from a United Kingdom study.弗雷明汉心血管风险方程和英国前瞻性糖尿病研究(UKPDS)风险评估模型对新诊断2型糖尿病患者冠心病的预后价值:一项英国研究的结果
Diabet Med. 2005 May;22(5):554-62. doi: 10.1111/j.1464-5491.2005.01494.x.
4
Development of a prediction model for fatal and non-fatal coronary heart disease and cardiovascular disease in patients with newly diagnosed type 2 diabetes mellitus: the Basque Country Prospective Complications and Mortality Study risk engine (BASCORE).新诊断2型糖尿病患者致命性和非致命性冠心病及心血管疾病预测模型的开发:巴斯克地区前瞻性并发症和死亡率研究风险引擎(BASCORE)
Diabetologia. 2014 Nov;57(11):2324-33. doi: 10.1007/s00125-014-3370-1. Epub 2014 Sep 12.
5
Assessing 10-Year Cardiovascular Disease Risk in Malaysians With Type 2 Diabetes Mellitus: Framingham Cardiovascular Versus United Kingdom Prospective Diabetes Study Equations.评估马来西亚 2 型糖尿病患者的 10 年心血管疾病风险:弗雷明汉心血管风险与英国前瞻性糖尿病研究方程。
Asia Pac J Public Health. 2019 Oct;31(7):622-632. doi: 10.1177/1010539519873487. Epub 2019 Sep 19.
6
Comparison of the Framingham and United Kingdom Prospective Diabetes Study cardiovascular risk equations in Australian patients with type 2 diabetes from the Fremantle Diabetes Study.弗雷曼特尔糖尿病研究中澳大利亚2型糖尿病患者的弗雷明汉心血管风险方程与英国前瞻性糖尿病研究心血管风险方程的比较。
Med J Aust. 2009 Feb 16;190(4):180-4. doi: 10.5694/j.1326-5377.2009.tb02684.x.
7
Impact of metabolic surgery on 10-year cardiovascular disease risk in Chinese individuals with type 2 diabetes.代谢手术对中国 2 型糖尿病患者 10 年心血管疾病风险的影响。
Surg Obes Relat Dis. 2021 Mar;17(3):498-507. doi: 10.1016/j.soard.2020.11.013. Epub 2020 Nov 20.
8
External validation of the UKPDS risk engine in incident type 2 diabetes: a need for new type 2 diabetes-specific risk equations.UKPDS 风险引擎在新诊断 2 型糖尿病中的外部验证:需要新的 2 型糖尿病特异性风险方程。
Diabetes Care. 2014 Feb;37(2):537-45. doi: 10.2337/dc13-1159. Epub 2013 Oct 2.
9
The validation of cardiovascular risk scores for patients with type 2 diabetes mellitus.心血管风险评分在 2 型糖尿病患者中的验证。
Heart. 2015 Feb;101(3):222-9. doi: 10.1136/heartjnl-2014-306068. Epub 2014 Sep 25.
10
Comparison of three different methods of assessing cardiovascular disease risk in New Zealanders with Type 2 diabetes mellitus.新西兰2型糖尿病患者三种不同心血管疾病风险评估方法的比较。
N Z Med J. 2008 Sep 5;121(1281):49-57.

引用本文的文献

1
Lipidomic analysis reveals metabolism alteration associated with subclinical carotid atherosclerosis in type 2 diabetes.脂质组学分析揭示了2型糖尿病患者亚临床颈动脉粥样硬化相关的代谢改变。
Cardiovasc Diabetol. 2025 Apr 2;24(1):152. doi: 10.1186/s12933-025-02701-z.
2
Precision prognostics for cardiovascular disease in Type 2 diabetes: a systematic review and meta-analysis.2型糖尿病心血管疾病的精准预后:一项系统评价与荟萃分析
Commun Med (Lond). 2024 Jan 22;4(1):11. doi: 10.1038/s43856-023-00429-z.
3
External validation of the UK prospective diabetes study (UKPDS) risk engine in patients with type 2 diabetes identified in the national diabetes program in Iran.

本文引用的文献

1
The Framingham and UK Prospective Diabetes Study (UKPDS) risk equations do not reliably estimate the probability of cardiovascular events in a large ethnically diverse sample of patients with diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron-MR Controlled Evaluation (ADVANCE) Study.弗雷明汉和英国前瞻性糖尿病研究(UKPDS)风险方程不能可靠地估计在一个大型种族多样化的糖尿病患者样本中发生心血管事件的概率:糖尿病和血管疾病的行动:培哚普利和米格列醇的控制评估(ADVANCE)研究。
Diabetologia. 2010 May;53(5):821-31. doi: 10.1007/s00125-010-1681-4. Epub 2010 Feb 17.
2
Prediction of coronary heart disease risk in a general, pre-diabetic, and diabetic population during 10 years of follow-up: accuracy of the Framingham, SCORE, and UKPDS risk functions: The Hoorn Study.10 年随访期间一般、糖尿病前期和糖尿病患者人群的冠心病风险预测:弗雷明汉、SCORE 和 UKPDS 风险函数的准确性:霍恩研究。
Diabetes Care. 2009 Nov;32(11):2094-8. doi: 10.2337/dc09-0745.
3
在伊朗国家糖尿病项目中识别出的2型糖尿病患者中对英国前瞻性糖尿病研究(UKPDS)风险评估模型进行外部验证。
J Diabetes Metab Disord. 2023 May 25;22(2):1145-1150. doi: 10.1007/s40200-023-01224-2. eCollection 2023 Dec.
4
First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists : A Cost-Effectiveness Study.钠-葡萄糖共转运蛋白 2 抑制剂和胰高血糖素样肽-1 受体激动剂治疗 2 型糖尿病的一线治疗:成本效益研究。
Ann Intern Med. 2022 Oct;175(10):1392-1400. doi: 10.7326/M21-2941. Epub 2022 Oct 4.
5
The Korean Hypertension Cohort study: design and baseline characteristics.韩国高血压队列研究:设计和基线特征。
Korean J Intern Med. 2021 Sep;36(5):1115-1125. doi: 10.3904/kjim.2020.551. Epub 2021 Jul 22.
6
Sodium-glucose cotransporter 2 inhibitors as an add-on therapy to insulin for type 1 diabetes mellitus: Meta-analysis of randomized controlled trials.钠-葡萄糖共转运蛋白 2 抑制剂作为 1 型糖尿病胰岛素的附加治疗:随机对照试验的荟萃分析。
Acta Diabetol. 2021 Jul;58(7):869-880. doi: 10.1007/s00592-021-01686-x. Epub 2021 Mar 2.
7
Identification of Plasma Inositol and Indoxyl Sulfate as Novel Biomarker Candidates for Atherosclerosis in Patients with Type 2 Diabetes. -Findings from Metabolome Analysis Using GC/MS.使用 GC/MS 进行代谢组学分析鉴定出 2 型糖尿病患者动脉粥样硬化的新型生物标志物候选物——肌醇和吲哚硫酸。
J Atheroscler Thromb. 2020 Oct 1;27(10):1053-1067. doi: 10.5551/jat.52506. Epub 2020 Jan 25.
8
Performance of the UKPDS Outcomes Model 2 for Predicting Death and Cardiovascular Events in Patients with Type 2 Diabetes Mellitus from a German Population-Based Cohort.基于德国人群队列的 2 型糖尿病患者 UKPDS 结局模型 2 预测死亡和心血管事件的性能。
Pharmacoeconomics. 2019 Dec;37(12):1485-1494. doi: 10.1007/s40273-019-00822-4.
9
Clinical utility of carotid ultrasonography: Application for the management of patients with diabetes.颈动脉超声检查的临床应用:用于糖尿病患者的管理。
J Diabetes Investig. 2019 Jul;10(4):883-898. doi: 10.1111/jdi.13042. Epub 2019 Apr 15.
10
Identification of Metabolites Associated with Onset of CAD in Diabetic Patients Using CE-MS Analysis: A Pilot Study.采用 CE-MS 分析鉴定糖尿病患者 CAD 发病相关的代谢物:一项初步研究。
J Atheroscler Thromb. 2019 Mar 1;26(3):233-245. doi: 10.5551/jat.42945. Epub 2018 Aug 1.
Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial.常规降压与强化血糖控制对 2 型糖尿病患者大血管和微血管结局的联合影响:来自 ADVANCE 试验的新结果。
Diabetes Care. 2009 Nov;32(11):2068-74. doi: 10.2337/dc09-0959. Epub 2009 Aug 3.
4
Cardiovascular risk assessment scores for people with diabetes: a systematic review.糖尿病患者的心血管风险评估分数:一项系统综述
Diabetologia. 2009 Oct;52(10):2001-14. doi: 10.1007/s00125-009-1454-0. Epub 2009 Jul 24.
5
Predicting the 30-year risk of cardiovascular disease: the framingham heart study.预测心血管疾病的30年风险:弗雷明汉心脏研究
Circulation. 2009 Jun 23;119(24):3078-84. doi: 10.1161/CIRCULATIONAHA.108.816694. Epub 2009 Jun 8.
6
Prognosis and prognostic research: application and impact of prognostic models in clinical practice.预后与预后研究:预后模型在临床实践中的应用与影响
BMJ. 2009 Jun 4;338:b606. doi: 10.1136/bmj.b606.
7
Cohort profile: the EPIC-NL study.队列简介:EPIC-NL研究。
Int J Epidemiol. 2010 Oct;39(5):1170-8. doi: 10.1093/ije/dyp217. Epub 2009 May 29.
8
Prognosis and prognostic research: validating a prognostic model.预后与预后研究:验证一个预后模型。
BMJ. 2009 May 28;338:b605. doi: 10.1136/bmj.b605.
9
Performance of the UK Prospective Diabetes Study Risk Engine and the Framingham Risk Equations in Estimating Cardiovascular Disease in the EPIC- Norfolk Cohort.英国前瞻性糖尿病研究风险引擎和弗雷明汉风险方程在评估欧洲癌症与营养前瞻性调查诺福克队列心血管疾病方面的表现。
Diabetes Care. 2009 Apr;32(4):708-13. doi: 10.2337/dc08-1918. Epub 2008 Dec 29.
10
Risk prediction of cardiovascular disease in type 2 diabetes: a risk equation from the Swedish National Diabetes Register.2型糖尿病患者心血管疾病的风险预测:来自瑞典国家糖尿病登记处的风险方程
Diabetes Care. 2008 Oct;31(10):2038-43. doi: 10.2337/dc08-0662. Epub 2008 Jun 30.